2025
Evaluating the association between routine pneumococcal vaccination and COVID-19 severity among older adults in the United States: A case control study
Prunas O, Tiu A, Shioda K, Bansal S, Weinberger D. Evaluating the association between routine pneumococcal vaccination and COVID-19 severity among older adults in the United States: A case control study. Vaccine X 2025, 24: 100622. DOI: 10.1016/j.jvacx.2025.100622.Peer-Reviewed Original ResearchCOVID-19 patientsCase-control studyIntensive care unitSevere respiratory symptomsPneumococcal vaccineSevere outcomesRespiratory symptomsOdds of progressionReceipt of pneumococcal vaccinationCOVID-19 severitySevere COVID-19 outcomesLogistic regression modelsSevere acute respiratory syndrome coronavirus 2Streptococcus pneumoniaeAcute respiratory syndrome coronavirus 2Non-severeRespiratory syndrome coronavirus 2Care unitControlled studiesPatientsSyndrome coronavirus 2COVID-19 outcomesSARS-CoV-2VaccineCoronavirus 2
2024
Rectourethral fistula after perirectal spacer placement requiring pelvic exenteration
Shah Y, Lokeshwar S, Brutus N, Sterling J. Rectourethral fistula after perirectal spacer placement requiring pelvic exenteration. BMJ Case Reports 2024, 17: e263333. PMID: 39719384, DOI: 10.1136/bcr-2024-263333.Peer-Reviewed Original ResearchConceptsPelvic exenterationRectourethral fistulaSpacer placementRectal radiation doseRobotic pelvic exenterationProstate cancer treatmentManagement of complicationsImprove cancer controlRectal toxicityGastrointestinal toxicitySpacer useClinical benefitFecal diversionSevere complicationsPostmarketing dataPatient counselingCancer controlRadiation doseCancer treatmentSevere outcomesLack of evidenceEarly identificationExenterationPhysician techniqueFistulaCoverage with Influenza, Respiratory Syncytial Virus, and COVID-19 Vaccines Among Nursing Home Residents — National Healthcare Safety Network, United States, November 2024
Reses H, Segovia G, Dubendris H, Barbre K, Ananth S, Lape-Newman B, Wong E, Stillions M, Rowe T, Mothershed E, Wallender E, Twentyman E, Wiegand R, Patel P, Benin A, Bell J. Coverage with Influenza, Respiratory Syncytial Virus, and COVID-19 Vaccines Among Nursing Home Residents — National Healthcare Safety Network, United States, November 2024. MMWR Morbidity And Mortality Weekly Report 2024, 73: 1052-1057. PMID: 39570790, PMCID: PMC11581205, DOI: 10.15585/mmwr.mm7346a2.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusRespiratory syncytial virus vaccineNational Healthcare Safety NetworkSyncytial virusVaccination coverageSusceptible to severe outcomesHealth and Human Services regionsRespiratory virus seasonCOVID-19 vaccineCDC's National Healthcare Safety NetworkInfluenza vaccineVirus seasonSevere complicationsRespiratory virusesAssociated with respiratory illnessInfluenzaNursing home residentsSafety NetworkRespiratory illnessSevere outcomesReport vaccinationElevated riskSARS-CoV-2VaccineIndex levelsEffectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024
C K, Surie D, Lauring A, Martin E, Leis A, Papalambros L, Gaglani M, Columbus C, Gottlieb R, Ghamande S, Peltan I, Brown S, Ginde A, Mohr N, Gibbs K, Hager D, Saeed S, Prekker M, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Khan A, Hough C, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Parikh B, Exline M, Vaughn I, Ramesh M, Safdar B, Mosier J, Harris E, Shapiro N, Felzer J, Zhu Y, Grijalva C, Halasa N, Chappell J, Womack K, Rhoads J, Baughman A, Swan S, Johnson C, Rice T, Casey J, Blair P, Han J, Ellington S, Lewis N, Thornburg N, Paden C, Atherton L, Self W, Dawood F, DeCuir J. Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024. Clinical Infectious Diseases 2024, ciae405. PMID: 39107255, DOI: 10.1093/cid/ciae405.Peer-Reviewed Original ResearchInvasive mechanical ventilationIntensive care unitCase-patientsOdds of severe outcomesCOVID-19 vaccineLogistic regressionOdds of ICU admissionCOVID-19 vaccine dosesControl-patientsAnalyzed patientsImmune escapeCase-control designVaccine compositionMechanical ventilationClinical severityICU admissionVaccine doseCare unitTest-negativeVaccine effectivenessSevere outcomesCOVID-19-like illnessCOVID-19 vaccine effectivenessSARS-CoV-2HospitalAcute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection
Woodruff R, Melgar M, Pham H, Sperling L, Loustalot F, Kirley P, Austin E, Yousey-Hindes K, Openo K, Ryan P, Brown C, Lynfield R, Davis S, Barney G, Tesini B, Sutton M, Talbot H, Zahid H, Kim L, Havers F, Rowlands J, Spina N, Engesser K, Salazar-Sanchez Y, George A, Staten H, Bleecker M, Leegwater L, Tellez Nunez V, Falkowski A, Felsen C, Licherdell E, St George K, Pacheco F, Desiato J, Labozzo N, Zmek E, Alden N, Strayhorn N, Fawcett E, Surell C, Como-Sabetti K, Mumm E, Bilski K, Markus T, Ndi D, Billings K. Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection. JAMA Internal Medicine 2024, 184: 602-611. PMID: 38619857, PMCID: PMC11019447, DOI: 10.1001/jamainternmed.2024.0212.Peer-Reviewed Original ResearchRespiratory syncytial virus infectionRespiratory syncytial virusRespiratory syncytial virus seasonAcute cardiac eventsCardiac eventsWeighted estimated prevalenceIn-Hospital DeathAdjusted risk ratiosIntensive care unitClassification of diseasesCross-sectional studyHospitalized adultsCardiac complicationsRSV infectionRSV diseaseLaboratory-confirmed RSV infectionOlder adultsCases of RSV infectionReceipt of invasive mechanical ventilationCardiovascular diseaseIntensive care unit admissionSevere outcomesEstimated prevalenceAcute heart failurePotential cardiac complicationsGender differences in PTSD severity and pain outcomes: Baseline results from the LAMP trial
Friedman J, Taylor B, Campbell E, Allen K, Bangerter A, Branson M, Bronfort G, Calvert C, Cross L, Driscoll M, Evans R, Ferguson J, Haley A, Hennessy S, Meis L, Burgess D. Gender differences in PTSD severity and pain outcomes: Baseline results from the LAMP trial. PLOS ONE 2024, 19: e0293437. PMID: 38753651, PMCID: PMC11098421, DOI: 10.1371/journal.pone.0293437.Peer-Reviewed Original ResearchConceptsPain outcomesPost-traumatic stress disorder symptomsChronic painPost-traumatic stress disorderWomen veteransChronic pain clinical trialsPain clinical trialsSensation of painHierarchical linear regression modelsGender differencesPain intensityPain catastrophizingPain interferenceClinical trialsPainAssociated with higher levelsComorbid conditionsExamined gender differencesLinear regression modelsSevere outcomesMultivariate modelMutual maintenanceClinical implicationsSymptomsVeteransClinical outcomes and immunological response to SARS-CoV-2 infection among people living with HIV
Amegashie E, Asamoah P, Ativi L, Adusei-Poku M, Bonney E, Tagoe E, Paintsil E, Torpey K, Quaye O. Clinical outcomes and immunological response to SARS-CoV-2 infection among people living with HIV. Experimental Biology And Medicine 2024, 249: 10059. PMID: 38628843, PMCID: PMC11020089, DOI: 10.3389/ebm.2024.10059.Peer-Reviewed Original ResearchConceptsLevels of inflammatory markersResponse to SARS-CoV-2 infectionClinical outcomesSARS-CoV-2 infectionCo-InfectionInflammatory markersSARS-CoV-2HIV patients co-infectedImmune response to SARS-CoV-2 infectionCD4<sup>+</sup> countInitiation of ARTT cell exhaustionPatients co-infectedSevere outcomesAssociated with severe outcomesStudy assessed risk factorsMono-infected individualsResponse to SARS-CoV-2Respiratory tract infectionsImmunological response to SARS-CoV-2Immunological response to SARS-CoV-2 infectionAfrican American raceChronic kidney diseaseIntensive care unitPositive conversion rateThe impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study
Castellano C, Sun T, Ravindranathan D, Hwang C, Balanchivadze N, Singh S, Griffiths E, Puzanov I, Ruiz‐Garcia E, Vilar‐Compte D, Cárdenas‐Delgado A, McKay R, Nonato T, Ajmera A, Yu P, Nadkarni R, O’Connor T, Berg S, Ma K, Farmakiotis D, Vieira K, Arvanitis P, Saliby R, Labaki C, Zarif T, Wise‐Draper T, Zamulko O, Li N, Bodin B, Accordino M, Ingham M, Joshi M, Polimera H, Fecher L, Friese C, Yoon J, Mavromatis B, Brown J, Russell K, Nanchal R, Singh H, Tachiki L, Moria F, Nagaraj G, Cortez K, Abbasi S, Wulff‐Burchfield E, Puc M, Weissmann L, Bhatt P, Mariano M, Mishra S, Halabi S, Beeghly A, Warner J, French B, Bilen M, Consortium F. The impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study. Cancer 2024, 130: 2191-2204. PMID: 38376917, PMCID: PMC11141719, DOI: 10.1002/cncr.35247.Peer-Reviewed Original ResearchConceptsSupplemental O<sub>2</sub>COVID-19 severityMetastatic cancerLogistic regression modelsMetastases to other sitesSite of metastatic cancerCOVID-19 outcomesMetastasis to boneRetrospective cohort studyAll-Cause MortalityIntensive care unitDay mortalityLymph nodesIncreased hospitalization ratesMechanical ventilationCohort studyMetastasisCare unitPatientsCancer metastasisRegression modelsCancerSevere outcomesCancer ConsortiumOrdinal logistic regression modelOverestimation of Severe Acute Respiratory Syndrome Coronavirus 2 Household Transmission in Settings of High Community Transmission: Insights From an Informal Settlement Community in Salvador, Brazil
Ticona J, Nery N, Hitchings M, Belitardo E, Fofana M, Dorión M, Victoriano R, Cruz J, Santana J, de Moraes L, Cardoso C, Ribeiro G, Reis M, Khouri R, Costa F, Ko A, Cummings D. Overestimation of Severe Acute Respiratory Syndrome Coronavirus 2 Household Transmission in Settings of High Community Transmission: Insights From an Informal Settlement Community in Salvador, Brazil. Open Forum Infectious Diseases 2024, 11: ofae065. PMID: 38516384, PMCID: PMC10957159, DOI: 10.1093/ofid/ofae065.Peer-Reviewed Original ResearchSARS-CoV-2Household transmissionRT-PCR positive casesSecondary attack rateAttack rateSARS-CoV-2 infectionSARS-CoV-2 Omicron variantRisk of infectionCommunity acquisitionTherapeutic optionsCOVID-19-related symptomsCase-finding studyHousehold contactsAcquisition of SARS-CoV-2Increased riskSymptom onsetSecondary infectionBooster vaccinationSevere outcomesBiweekly visitsHighest attack rateRT-PCRInfectionCOVID-19 severe outcomesOmicron BAFebrile infants aged ≤60 days: evaluation and management in the emergency department.
Palladino L, Woll C, Aronson P. Febrile infants aged ≤60 days: evaluation and management in the emergency department. Pediatric Emergency Medicine Practice 2024, 21: 1-28. PMID: 38266065.Peer-Reviewed Original ResearchConceptsInvasive bacterial infectionsBacterial infectionsManagement of febrile young infantsAmerican Academy of Pediatrics clinical practice guidelineYoung infantsFebrile young infantsPediatrics clinical practice guidelineEmergency departmentUrinary tract infectionRisk stratification toolPositive viral testClinical practice guidelinesTract infectionsViral testingEmergency cliniciansSevere outcomesAmerican AcademyInfectionPractice guidelinesInfantsDepartmentFeverEmergency
2023
Coverage with Influenza, Respiratory Syncytial Virus, and Updated COVID-19 Vaccines Among Nursing Home Residents — National Healthcare Safety Network, United States, December 2023
Reses H, Dubendris H, Haas L, Barbre K, Ananth S, Rowe T, Mothershed E, Hall E, Wiegand R, Lindley M, Meyer S, Patel S, Benin A, Kroop S, Srinivasan A, Bell J. Coverage with Influenza, Respiratory Syncytial Virus, and Updated COVID-19 Vaccines Among Nursing Home Residents — National Healthcare Safety Network, United States, December 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 1371-1376. PMID: 38127673, PMCID: PMC10754267, DOI: 10.15585/mmwr.mm7251a3.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusNursing home residentsNational Healthcare Safety NetworkRespiratory virus seasonHome residentsVaccination coverageRespiratory virusesSyncytial virusCDC's National Healthcare Safety NetworkCOVID-19COVID-19 vaccination coverageHuman Services (HHS) regionsCOVID-19 vaccineSARS-CoV-2RSV vaccineSevere complicationsRespiratory illnessSevere outcomesNursing homesEligible residentsVaccinationInfluenzaSafety NetworkOlder adultsVaccineCOVID-19–Associated Hospitalizations Among U.S. Adults Aged ≥65 Years — COVID-NET, 13 States, January–August 2023
Taylor C, Patel K, Patton M, Reingold A, Kawasaki B, Meek J, Openo K, Ryan P, Falkowski A, Bye E, Plymesser K, Spina N, Tesini B, Moran N, Sutton M, Talbot H, George A, Havers F, Team C, Team C, Kirley P, Armistead I, Yousey-Hindes K, Oosmanally N, Monroe M, Henderson J, D’Heilly P, Hancock E, Barney G, Bushey S, Billing L, Abdullah N, Schaffner W, Mendez E. COVID-19–Associated Hospitalizations Among U.S. Adults Aged ≥65 Years — COVID-NET, 13 States, January–August 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 1089-1094. PMID: 37796744, PMCID: PMC10564325, DOI: 10.15585/mmwr.mm7240a3.Peer-Reviewed Original ResearchConceptsCOVID-19-associated hospitalizationCOVID-19-Associated Hospitalization Surveillance NetworkCOVID-19-associated hospitalization ratesHospitalization ratesAge groupsIntensive care unit admissionMultiple underlying conditionsSevere COVID-19 diseasePromote early treatmentPositive SARS-CoV-2 testSARS-CoV-2 infectionPrevent SARS-CoV-2 infectionYounger age groupsClinical characteristicsUnit admissionUnderlying conditionEarly treatmentSARS-CoV-2 testingIncreased riskSevere COVID-19-associated outcomesSevere outcomesCOVID-19 hospitalizationElevated riskCOVID-19 diseaseBivalent vaccineSeverity of influenza-associated hospitalisations by influenza virus type and subtype in the USA, 2010–19: a repeated cross-sectional study
Sumner K, Masalovich S, O’Halloran A, Holstein R, Reingold A, Kirley P, Alden N, Herlihy R, Meek J, Yousey-Hindes K, Anderson E, Openo K, Monroe M, Leegwater L, Henderson J, Lynfield R, McMahon M, McMullen C, Angeles K, Spina N, Engesser K, Bennett N, Felsen C, Lung K, Shiltz E, Thomas A, Talbot H, Schaffner W, Swain A, George A, Rolfes M, Reed C, Garg S. Severity of influenza-associated hospitalisations by influenza virus type and subtype in the USA, 2010–19: a repeated cross-sectional study. The Lancet Microbe 2023, 4: e903-e912. PMID: 37769676, PMCID: PMC10872935, DOI: 10.1016/s2666-5247(23)00187-8.Peer-Reviewed Original ResearchConceptsInfluenza virus typeInfluenza-associated hospitalisationsInfluenza seasonInfluenza B virusICU admissionMechanical ventilationSevere outcomesOdds ratioVirus typeFluSurv-NETECMO useInfluenza vaccineB virusVirus infectionLaboratory-confirmed influenza virus infectionInfluenza Hospitalization Surveillance NetworkInfluenza B virus infectionPopulation-based surveillance systemComplete chart reviewEarly antiviral treatmentHospital-onset casesInfluenza-associated outcomesRepeated cross-sectional studyInfluenza vaccination statusB virus infectionTrends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY
Green A, Curtis H, Higgins R, Nab L, Mahalingasivam V, Smith R, Mehrkar A, Inglesby P, Drysdale H, DeVito N, Croker R, Rentsch C, Bhaskaran K, Tazare J, Zheng B, Andrews C, Bacon S, Davy S, Dillingham I, Evans D, Fisher L, Hickman G, Hopcroft L, Hulme W, Massey J, MacDonald O, Morley J, Morton C, Park R, Walker A, Ward T, Wiedemann M, Bates C, Cockburn J, Parry J, Hester F, Harper S, Douglas I, Evans S, Goldacre B, Tomlinson L, MacKenna B. Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY. BMJ Medicine 2023, 2: e000276. PMID: 36936265, PMCID: PMC9951378, DOI: 10.1136/bmjmed-2022-000276.Peer-Reviewed Original ResearchDescriptive cohort studyHigh-risk groupSevere outcomesHigh riskCohort studyHome residentsRisk groupsAntiviral drugsCOVID-19Community settingsMonoclonal antibodiesCasirivimab/imdevimabLow treatment coverageNHS regionProportion of patientsCOVID-19 infectionRoutine clinical dataOpenSAFELY platformUnvaccinated patientsClinical characteristicsLiver diseaseClinical dataTreatment coverageEligibility criteriaPatients
2022
Association Between Race/Ethnicity and COVID‐19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID‐19 Global Rheumatology Alliance
Ugarte‐Gil M, Alarcón G, Seet A, Izadi Z, Montgomery A, Duarte‐García A, Gilbert E, Valenzuela‐Almada M, Wise L, Sparks J, Hsu T, D'Silva K, Patel N, Sirotich E, Liew J, Hausmann J, Sufka P, Grainger R, Bhana S, Wallace Z, Jacobsohn L, Strangfeld A, Mateus E, Hyrich K, Gossec L, Carmona L, Lawson‐Tovey S, Kearsley‐Fleet L, Schaefer M, Machado P, Robinson P, Gianfrancesco M, Yazdany J. Association Between Race/Ethnicity and COVID‐19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID‐19 Global Rheumatology Alliance. Arthritis Care & Research 2022, 75: 53-60. PMID: 36239292, PMCID: PMC9874592, DOI: 10.1002/acr.25039.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusCOVID-19 outcomesRace/ethnicitySevere COVID-19 outcomesSystemic lupus erythematosus patientsImmunosuppressive drug useLupus erythematosus patientsCOVID-19 severityUS general populationLogistic regression modelsOrdinal logistic regression modelsGlucocorticoid doseDisease activityPandemic time periodSD ageLupus erythematosusPossible confoundersSevere outcomesMultivariable modelHigher oddsGeneral populationPatientsDrug useHealth disparitiesOutcome categoriesA MUC5B Gene Polymorphism, rs35705950-T, Confers Protective Effects Against COVID-19 Hospitalization but Not Severe Disease or Mortality
Verma A, Minnier J, Wan ES, Huffman JE, Gao L, Joseph J, Ho YL, Wu WC, Cho K, Gorman BR, Rajeevan N, Pyarajan S, Garcon H, Meigs JB, Sun YV, Reaven PD, McGeary JE, Suzuki A, Gelernter J, Lynch JA, Petersen JM, Zekavat SM, Natarajan P, Dalal S, Jhala DN, Arjomandi M, Gatsby E, Lynch KE, Bonomo RA, Freiberg M, Pathak GA, Zhou JJ, Donskey CJ, Madduri RK, Wells QS, Huang R, Polimanti R, Chang KM, Liao KP, Tsao PS, Wilson PWF, Hung A, O’Donnell C, Gaziano JM, Hauger RL, Iyengar S, Luoh SW, Initiative T. A MUC5B Gene Polymorphism, rs35705950-T, Confers Protective Effects Against COVID-19 Hospitalization but Not Severe Disease or Mortality. American Journal Of Respiratory And Critical Care Medicine 2022, 206: 1220-1229. PMID: 35771531, PMCID: PMC9746845, DOI: 10.1164/rccm.202109-2166oc.Peer-Reviewed Original ResearchConceptsCOVID-19 hospitalizationIdiopathic pulmonary fibrosisMillion Veteran ProgramHost Genetics InitiativeAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionGene polymorphismsSyndrome coronavirus 2 infectionCoronavirus 2 infectionConfer protective effectsCOVID-19 positivityCoronavirus disease (COVID-19) infectionElectronic health recordsMVP subjectsPneumonia eventsClinical outcomesPulmonary fibrosisCOVID-19 Host Genetics InitiativeClinical eventsSevere outcomesProtective effectSevere diseaseRs35705950Disease severityMVP participantsAnalytical Approaches to Uncover Genetic Associations for Rare Outcomes: Lessons from West Nile Neuroinvasive Disease
Cahill M, Montgomery R. Analytical Approaches to Uncover Genetic Associations for Rare Outcomes: Lessons from West Nile Neuroinvasive Disease. Methods In Molecular Biology 2022, 2585: 193-203. PMID: 36331775, PMCID: PMC9867870, DOI: 10.1007/978-1-0716-2760-0_17.Peer-Reviewed Original ResearchConceptsWest Nile neuroinvasive diseaseNeuroinvasive diseaseViral infectionWest Nile viral infectionSevere neuroinvasive diseaseMore severe outcomesGenetic factorsRare outcomesLimited cohort sizeSevere West Nile neuroinvasive diseaseWest Nile infectionVector-borne viral infectionSevere outcomesImmune responseSevere diseaseHigh riskFatal diseaseVaccine developmentInfectionDiseaseInfected humansWest NileSerious diseaseOutcomesCohort sizeReturn on Investment of the COVID-19 Vaccination Campaign in New York City
Sah P, Vilches T, Moghadas S, Pandey A, Gondi S, Schneider E, Singer J, Chokshi D, Galvani A. Return on Investment of the COVID-19 Vaccination Campaign in New York City. JAMA Network Open 2022, 5: e2243127. PMID: 36409495, PMCID: PMC9679875, DOI: 10.1001/jamanetworkopen.2022.43127.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccination campaignVaccination campaignIntensive care unit admissionCare unit admissionEmergency department visitsIndirect costsDecision analytical modelEmergency medical servicesCOVID-19 deathsHealth care expendituresUnit admissionDepartment visitsFuture COVID-19 outbreaksNew York CityOutpatient visitsVaccine uptakeSevere outcomesVaccination programPotential yearsMAIN OUTCOMEVaccinationHealth outcomesProbable casesSocietal perspectiveCare expendituresDrug use and severe outcomes among adults hospitalized with influenza, 2016–2019
Parisi C, Yousey‐Hindes K, Holstein R, O'Halloran A, Kirley P, Alden N, Anderson E, Kim S, McMahon M, Khanlian S, Spina N, Gaitan M, Shiltz E, Thomas A, Schaffner W, Talbot K, Crossland M, Cook R, Garg S, Meek J, Hadler J. Drug use and severe outcomes among adults hospitalized with influenza, 2016–2019. Influenza And Other Respiratory Viruses 2022, 17: e13052. PMID: 36300969, PMCID: PMC9835414, DOI: 10.1111/irv.13052.Peer-Reviewed Original ResearchConceptsSevere outcomesDrug useICU admissionMechanical ventilationInfluenza Hospitalization Surveillance NetworkInfluenza-associated outcomesSevere influenza outcomesPersistent public health problemChronic liver diseaseChronic lung diseasePublic health problemNon-Hispanic blacksLogistic regression modelsHispanics/LatinosSmoke tobaccoInfluenza vaccinationOpioid useImmunosuppressive conditionsInfluenza seasonSevere morbidityInfluenza infectionInfluenza outcomesLiver diseaseLung diseaseChronic conditionsFactors influencing the decision to receive seasonal influenza vaccination among US corporate non-healthcare workers
Aguolu OG, Willebrand K, Elharake JA, Qureshi HM, Kiti MC, Liu CY, Mesa A, Nelson K, Jenness S, Melegaro A, Ahmed F, Yildirim I, Malik FA, Lopman B, Omer SB. Factors influencing the decision to receive seasonal influenza vaccination among US corporate non-healthcare workers. Human Vaccines & Immunotherapeutics 2022, 18: 2122379. PMID: 36136345, PMCID: PMC9746537, DOI: 10.1080/21645515.2022.2122379.Peer-Reviewed Original ResearchConceptsInfluenza vaccinationNon-healthcare workersInfluenza vaccinePromotion messagesWorkplace vaccination programsSeasonal influenza vaccinationInfluenza vaccine acceptancePublic health authoritiesLogistic regression modelsInfluenza seasonPhysician recommendationVaccination acceptanceVaccine accessibilityVaccine acceptanceSevere outcomesVaccination programPromotion interventionsUS adultsWork absenceVaccinationVaccination decisionsHealth authoritiesSignificant mortalityUnderstanding predictorsSignificant predictors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply